8
Agenda
Merck
–Introduction
–Background
–Clinical Development Program
Efficacy
Resistance
Safety
Drug interactions
Risk Management Plan
Conclusions
FDA
–Summary of clinical efficacy, resistance and clinical
safety
–Concluding remarks